PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacolog...(aluations of medications for the treatme...)

Date:4/2/2008

aluations of medications for the treatment of a broad range of CNS and psychiatry disorders. Dr. Ereshefsky is a leader in CNS clinical study design and research methodologies, and has served on U.S. Food and Drug Administration (FDA) and United States Pharmacopeia (USP) advisory boards. Prior to joining PAREXEL, Dr. Ereshefsky was Chief Scientific Officer at California Clinical Trials. He was formerly Professor of Psychiatry and Pharmacology at The University of Texas Health Science Center in San Antonio, Texas in the United States. Previously, he was Associate Director of Research at San Antonio State Hospital, and held principal investigator and clinical consulting positions at several medical institutions. Dr. Ereshefsky received a Pharm.D. degree from the University of Southern California (USC), and completed his residency at the Los Angeles County-USC Medical Center. He currently serves on the Executive Committee of The International Society for CNS Clinical Trials and Methodology, and has served as Presidential Officer of the College of Psychiatric and Neurological Pharmacists. He is a frequent presenter, has authored more than 100 articles, and has held editorial advisory positions for major psychiatry, pharmacologic, and psychiatric pharmacy publications.

Dr. Malek Bajbouj is Board Certified in Psychiatry and Clinical Neurophysiology. He has expertise in CNS biomarkers and the development of new physiological procedures, including neurophysiological and neuroimaging measures used in cognitive function research. His research background also includes genetics, antidepressive stimulation techniques, and sleep medicine. Dr. Bajbouj is a Professor at the Charite University in Berlin, Germany, where he heads the Electroencephalography Lab and Neuromodulation Unit. He also serves as Co-Director of the Affective Disorder Module and the Sleep Laboratory at the university. Dr. Bajbouj is a permanent member of the university's Drug Commission and Doctoral Commi
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
2. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
3. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
4. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
5. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
6. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
7. PAREXEL International Announces 2-For-1 Stock Split
8. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
11. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities